Hetero, one of India's leading generic pharmaceutical companies and the world's largest producer of antiretroviral drugs, has launched the 3-in-1 combination drug in the domestic market. This Hyderabad-based company has introduced the drug under the brand name 'TAFFIC' for the treatment of human immunodeficiency virus (HIV) infection in adults. Taffic is a generic version of Gilead's Biktarvy and has been approved by the Drug Controller General of India (DCGI).

It is a combination of three medicines -- Bictegravir (50mg), Emtricitabine (200mg) and Tenofovir Alafenamide (25mg) that helps to prevent HIV from multiplying and works together to accomplish several important goals:

✔️ Prevent the virus from replicating and reduce viral load.
✔️ Help restore CD4 counts and immune function.
✔️ Reduce complications from HIV and improve survival.
✔️ Reduce the transmission of HIV to others.

The introduction of Taffic tablet (Generic Biktarvy) changed everything about HIV treatment and prevention. It has brought a sense of renewed hope for increased longevity in people living with HIV. In addition, it is 80–95 percent less expensive than their branded medicines and has provided a significant improvement in the overall quality of life of people living with HIV. Let’s take a look at the price of Taffic tablet and reduce out-of-pocket expenditure on medicines.
https://www.drugssquare.com/hiv-aids-medicines/taffic-tablet